scholarly journals Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

2011 ◽  
Vol 22 (8) ◽  
pp. 1812-1823 ◽  
Author(s):  
J. Beck ◽  
G. Procopio ◽  
E. Bajetta ◽  
U. Keilholz ◽  
S. Negrier ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Community Settings ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Expanded Access ◽  
Diverse Community

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

2019 ◽  
Author(s):  
Brian Rini ◽  
Sumanta K. Pal ◽  
Bernard J. Escudier ◽  
Michael B. Atkins ◽  
Thomas E. Hutson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study

scholarly journals A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

2014 ◽  
Vol 12 (3) ◽  
pp. 167-177.e2 ◽  
Author(s):  
David S. Hong ◽  
Michael S. Gordon ◽  
Wolfram E. Samlowski ◽  
Razelle Kurzrock ◽  
Nizar Tannir ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

2005 ◽  
Vol 57 (4) ◽  
pp. 533-539 ◽  
Author(s):  
Monika Jermann ◽  
Rolf A Stahel ◽  
Marc Salzberg ◽  
Thomas Cerny ◽  
Markus Joerger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Locally Advanced ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document